Introduction:
Compared with the industry lull of 2024, the first half of 2025 saw an undeniable volcanic eruption in China’s innovative-drug arena: in Q1 alone, the aggregate value of Chinese pharma cross-border out-licensing deals already equaled the full-year total for 2023. At the 2025 ASCO meeting, Chinese powerhouses—led by Innovent—delivered an impressive report card. China’s drug innovators are shaking off their “fast-follower” stereotype; their startling creativity has international giants such as Pfizer, AstraZeneca, and Merck on a buying spree in China.
1. Policy & Regulation: A Full-Chain Support System Takes Shape
Review & approval: the “30-Day Revolution”
In June, NMPA launched a 30-day fast track for clinical-trial applications covering Category 1 first-in-class drugs, rare-disease therapies, and globally synchronized projects. The timeline shrinks from 60 days to 30, provided companies pledge to start trials within 12 weeks—speeding R&D by roughly 40 percent. On 29 May alone the NMPA cleared eleven new drugs (including eight Category 1s), underscoring the efficiency sea-change.
Reimbursement: dual-track breakthrough
The National Healthcare Security Administration unveiled a “1 + 3 + N” multilevel payment system:
- Basic medical-insurance dynamic expansion: 91 drugs (including 38 global first-in-class) will be added to the 2025 list.
- Commercial-insurance Class-C catalogue: for the first time, an independent list for private health-insurance coverage of high-value oncology and rare-disease drugs—set to launch in September—offers incremental payment channels for drug makers.
- Local pilot programs: Guangzhou, for example, grants national tender drugs standalone budgets, higher reimbursement ratios, and waives outpatient caps, easing the “hospital-entry bottleneck.”
Global convergence
New data-exclusivity rules grant up to six years of protection for originator drugs. Beijing, Shenzhen, and other hubs have compressed trial-start timelines to 20 weeks, with 90 percent ethics-review mutual recognition.
2. Product Launches: A Surge of Home-grown “Global Firsts”
By end-June 2025, the NMPA had cleared 38 innovative drugs (including four TCM innovations) spanning oncology, metabolic, and autoimmune diseases. On 29 May alone it set a one-day record of eleven approvals, e.g.:
- Famitinib malate (Hengrui): a multikinase TKI, now approved with camrelizumab for platinum-failed, bevacizumab-naïve recurrent or metastatic cervical cancer.
- Phosphorolapitant palonosetron injection (brand: Ruitan Ning, Hengrui subsidiary Sundia): prevention of acute & delayed CINV with HEC.
- Rikang trastuzumab emtansine (brand: Avida, SHR-A1811, HER2-ADC, Hengrui/Sundia): conditionally approved for HER2-mutant unresectable or metastatic NSCLC after ≥1 systemic therapy.
- Lovometinib tablets (brand: Fumaining, MEK1/2 inhibitor, Fosun): approved for adult LCH/histiocytic tumors and pediatric NF1-PN (≥2 y).
- Fuvixilimab citrate capsules (brand: Futuoning, CDK4/6 inhibitor, Fosun subsidiary Aohong): with fulvestrant for HR+ / HER2- metastatic breast cancer progressing on endocrine therapy.
3. Corporate Moves: From “Tech Export” to “Ecosystem Co-creation”
License-out 3.0 era—Q1 2025 cross-border deals hit USD 36.9 billion. Structures are shifting from regional rights sales to global co-development:
- Hansoh Pharma “dual stars go global”
- HS-20094 GLP-1/GIP bispecific licensed globally (ex-Greater China) to Regeneron: USD 80 million upfront + USD 1.93 billion milestones.
- Pre-clinical oral GLP-1 HS-10535 snapped up by Merck: USD 112 million upfront + USD 1.9 billion milestones.
- 3SBio smashes upfront record
PD-1/VEGF bispecific SSGJ-707 licensed to Pfizer for USD 6.05 billion total, with USD 1.25 billion upfront. - CStone “borrows big ships”
Sugelezumab (PD-L1) after US/EU approvals now sublicensed to Latin-American leader SteinCares for ten countries via upfront + milestones + supply revenue. - CSPC “pipeline securitization”
- 30 May: negotiating three deals worth ~USD 5 billion covering EGFR-ADC, etc.
- 13 Jun: research pact with AstraZeneca—USD 110 million upfront + up to USD 1.62 billion R&D milestones + USD 3.6 billion sales milestones.
4. R&D Progress: From “Data Export” to “Standard Setting”
ASCO: rise of China
The 2025 ASCO meeting featured 73 Chinese studies in oral sessions (vs. only one in 2015) and 11 late-breaking abstracts. Innovent’s PD-1/IL-2 bispecific IBI363 showed 12-month OS of 70.9 percent at 3 mg/kg in advanced NSCLC—data poised to redefine global oncology standards.
Guidelines & dual filings
- CStone’s sugelezumab gained ESMO guideline endorsement as a first-line NSCLC option—the first Chinese PD-L1 drug in an intl guideline.
- CSPC’s SYH2059 tablets received both US and China IND clearances for interstitial lung disease.
5. Conclusion
Key traits of China’s innovative-drug sector in 1H 2025:
- Policy-driven boom—review, payment, and data-protection reforms form a full-chain support ecosystem.
- Globalization leap—license-out shifts from volume growth to value escalation (high-value targets, mega-deals).
- Clinical impact—stronger data output on international stages like ASCO aligns domestic R&D with global standards.
[Disclaimer]: The above content reflects analysis of publicly available information, expert insights, and BCC research. It does not constitute investment advice. BCC is not responsible for any losses resulting from reliance on the views expressed herein. Investors should exercise caution.